DNTH

Dianthus Therapeutics, Inc. Common Stock

52.44

USD

DNTH Earnings Reports

Positive Surprise Ratio

DNTH beat 21 of 30 last estimates.

70%

Next Report

Date of Next Report

Mar 09, 2026

Estimate for Q4 25 (Revenue/ EPS)

$406.90K

-$1.08

Implied change from Q3 25 (Revenue/ EPS)

+2.75%

+11.34%

Implied change from Q4 24 (Revenue/ EPS)

-59.27%

+33.33%

Dianthus Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, DNTH reported earnings of -0.97 USD per share (EPS) for Q3 25, missing the estimate of -0.87 USD, resulting in a -10.28% surprise. Revenue reached 396.00 thousand, compared to an expected 587.93 thousand, with a -32.64% difference. The market reacted with a +8.00% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 16 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 406.90 thousand USD, implying an increase of 11.34% EPS, and increase of 2.75% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Twist Bioscience Corporation Common Stock

Report Date

Feb 02, 2026 For Q1 26

Estimate

-$0.43

Actual

-$0.50

Surprise

-14.00%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were Dianthus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Dianthus Therapeutics, Inc. Common Stock reported EPS of -$0.97, missing estimates by -10.28%, and revenue of $396.00K, -32.64% below expectations.

How did the market react to Dianthus Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 8%, changed from $33.73 before the earnings release to $36.43 the day after.

When is Dianthus Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 09, 2026.

What are the forecasts for Dianthus Therapeutics, Inc. Common Stock's next earnings report?

Based on 16 analysts, Dianthus Therapeutics, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $406.90K for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.